See below for the ongoing trial.

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated with Tuberous Sclerosis Complex (TSC)

A new clinical trial for individuals with TSC and facial angiofibromas who are 6 – 65 years old. Individuals who have used oral rapamycin/sirolimus, everolimus, or temsirolimus within 3 months of enrollment or have had laser surgery within 6 months of enrollment are not eligible to participate.

These locations in the United States are recruiting participants:

University of California San Diego
La Jolla, California, United States, 92037
Contact: Jessica Reit jreit@ucsd.edu
Principal Investigator: Doris Trauner

All Children’s Research Institute
Saint Petersburg, Florida, United States, 33701
Contact: Bailey Box  727-767-2946 bbox1@jhmi.edu
Contact: Brook Olmo 727-767-2423  bolmo1@jhmi.edu
Principal Investigator: Stacie Stapleton

Spectrum Health
Grand Rapids, Michigan, United States, 49503
Contact: Christopher L Russell christopher.russell@spectrumhealth.org
Principal Investigator: Steven DeRoos

Mayo Clinic
Rochester, Minnesota, United States, 55905
Contact: Katrina Pierce, CCRP 507-266-1078 pierce.katrina@mayo.edu
Principal Investigator: Megha M Tollefson, MD
Sub-Investigator: Lily C Wong-Kisiel, MD

University of Virginia
Charlottesville, Virginia, United States, 22903
Contact: Stacy Thompson src2h@hscmail.mcc.virginia.edu
Principal Investigator: Derek Bauer